Status In progress
Process CDF Review
ID number 1583

Provisional Schedule

Committee meeting: 1 25 February 2020
Expected publication 13 May 2020

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
17 October 2019 Invitation to participate
30 August 2019 In progress, Obinutuzumab in combination with bendamustine within its marketing authorisation for treating follicular lymphoma that is refractory to rituximab or a rituximab-containing regimen.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance